Automation and Robotics: Driving Industrial Performance at Mora Group

Automation and robotics continue to profoundly transform the industrial landscape. At Mora Group, these technologies are embedded at the heart of our production lines to ensure precision, performance, and cleanroom compliance. Through the insights of Christophe Basset, discover how automation has become a strategic asset for optimizing processes in the plastic injection molding industry.

Hello Christophe, could you briefly introduce yourself?

I’m Christophe Basset, Industrial Methods Manager at Mora Group since 2006. My role is to design, define, and implement all the processes and industrial resources required for the production of injected parts — except for the molds. I oversee the definition of production lines, injection presses, and associated robots, as well as the creation of controlled atmosphere areas (ISO 7 and ISO 8). I’m also involved in integrating post-injection assembly and inspection machines. My mission is to support Mora Group in developing and implementing automation and robotics solutions tailored to our clients’ needs and the demands of their markets.


Christophe, can you explain the difference between robotization and automation? What does each term actually mean?

Automatic counting system

We can distinguish between automation and robotization. Automation often involves robotics, but not always. Some steps, such as packaging, can be fully automated without any direct use of robots.

In our field of plastic injection molding, the first step after injection is to unload the molded parts. This can, of course, be done using dedicated robots, but also through automatic systems that don’t rely on robotics. For example, we use counting and packaging systems combined with conveyors, which allow us to efficiently manage the continuous production flow.

What are the concrete benefits of automation in the plastic injection molding industry?

One of the main benefits of automation is the optimization of production cycles and the associated workforce. Beyond productivity, it also improves reliability and quality. For example, by automating the counting of parts, Mora Group ensures that each package contains the exact number of units required. Another key advantage is the elimination of direct contact between molded parts and operators’ hands during final packaging. This level of control significantly reduces the risk of product contamination.

Finally, this evolution has also improved ergonomics for operators. Previously, they had to manually place boxes on scales, monitor the filling process, and replace containers once they were full. This repetitive and physically demanding task has been replaced by automated systems equipped with conveyors and in-line weighing. Operators are now freed from these time-consuming operations and can focus on higher value-added tasks.

What types of robots are used at Mora Group, and what are their main functions?

Coming back to robotics, we use several different types of robots:

  • So-called “cartesian” robots

Particularly for productions intended for the automotive sector. These robots operate on three axes (X, Y, and Z), similar to a mathematical coordinate system, and are the most common type used in the plastics industry. Their arm moves up and down along the vertical axis, while a horizontal beam allows them to travel and perform part pick-and-place operations.

Although this system can be bulky, it allows for extended reach and is perfectly suited to managing multiple part references. Another advantage is its ability to handle heavy loads.

Cartesian robot for unloading and multi-reference sorting (automotive sector)
Side-entry robot (in-mold cycle)
  • High-speed side-entry robots

These robots are used for productions with very short cycle times. Their purpose is to minimize the robot’s intervention time inside the mold and avoid impacting the overall injection cycle duration.

  • 6-axis robots

In France, Mora Group primarily deploys 6-axis robots, especially for medical applications. These robots offer multiple advantages:

  • Their compact design makes them particularly well-suited for cleanrooms, where every cubic meter must be optimized to minimize the air volume handled by filtration systems.
  • They also stand out for their low particle emission and ease of cleaning. Some models used by Mora Group can operate in environments up to ISO Class 5, ensuring full compliance with the stringent standards of the medical and pharmaceutical industries.
  • Most importantly, they provide greater freedom of movement, making them ideal for post-injection operations.
Automated inspection and packaging station (Mora France site)

Today, the French site in Chambost-Allières is equipped with 6-axis robots used for part unloading as well as specific tasks such as vision-based quality control, packaging, and pad printing. This versatility enables cleanroom integration of finishing and customization stages while maintaining the highest standards of cleanliness and traceability.

What criteria guide your choices between the different types of robots and automation solutions?

The systems implemented to optimize existing production lines are primarily driven by productivity gains, balanced against the cost of the required investment.

When it comes to new projects, installations are always designed around the specific characteristics of each product. The choice depends on multiple parameters such as the associated machine, type of production, cycle time, number of part references to manage, and the operations to be performed on the product (assembly, sorting, inspection, etc.). Robots provide the flexibility needed to adapt to these requirements and ensure solutions that are perfectly aligned with each product’s specifications.

Automatic courtesy mirror assembly line (Mora Portugal site)

Semi-automatic headrest sleeve assembly machine (Mora Romania site)

For each new project, and according to the specific needs of the client and the product, Mora Group develops complete automatic or semi-automatic assembly lines, as well as special-purpose machines — particularly for assembling components for the automotive industry at our Portuguese and Romanian sites. These dedicated systems ensure both assembly reliability and strict adherence to the cycle times and cost requirements demanded by the sector.

How are robots redefining industrial performance at Mora Group?

Mora Group continuously upgrades its robot fleet and automated lines to meet client needs and adapt to upcoming projects, always with a focus on staying at the forefront of existing technologies.

The company remains attentive to emerging innovations, particularly artificial intelligence, which is already integrated into our camera-based inspection systems. These systems automatically verify part quality at the end of the injection process, offering unmatched reliability and speed. AI enhances inspection accuracy, reduces human error, and ensures consistent batch compliance.

Data processing software applied to injection molding already enables continuous self-diagnosis of machines. These advancements are paving the way for more predictive industrial processes — capable of anticipating deviations and adjusting production parameters in real time.

Artificial intelligence already plays, and will increasingly play, a key role in automation — and robots will undoubtedly be part of that evolution.

To be continued…

Laser welding and microfluidics: precision engineering at the core of Mora Group’s expertise

Microfluidics is evolving rapidly, driven by major challenges in healthcare and diagnostics. MORA Group is rising to meet these challenges by combining its expertise in plastic injection molding and laser welding. Through the insights of Vincent Collard, discover how laser welding is becoming a strategic lever in the assembly of microfluidic chips.

Hello Vincent, could you briefly introduce yourself?

I’m Vincent Collard, Technical Director at MORA Group and a mechanical engineer graduated from UTC Compiègne.
After an initial experience in subcontracting, I spent 15 years in the automotive industry, designing engine sensors and mechatronic systems for manufacturers such as PSA, Renault, BMW, and Ford. I led teams and managed projects from design through to production launch.
I then took on new challenges in the renewable energy sector, overseeing large-scale projects for EDF and Aéroports de Paris.
Today, I bring this expertise to MORA’s clients, supporting them in their most complex projects with precision and high standards.

Vincent, could you explain what laser welding of microfluidic chips made of COC involves?

To begin with, COC (Cyclic Olefin Copolymer) is a plastic material particularly well-suited for microfluidic devices. It stands out for its excellent optical transparency, biocompatibility, and low chemical leachability. These properties make it a credible and increasingly common alternative to glass, which has historically been used for such applications. With performance characteristics similar to glass, COC is becoming a strategic choice for the design of microfluidic chips.

What is a microfluidic chip, and what are its main applications?

Microfluidic chips are small devices used to handle very small volumes of liquids. They are at the core of numerous applications in medical diagnostics and biology. Today, this technology is experiencing significant growth, particularly in the areas of screening and analytical testing.

Microfluidic chips operate somewhat like the COVID test cassettes that most people are familiar with. The chips are inserted into diagnostic devices, just like the COVID cassettes, to deliver fast and accurate analysis results. The tested samples typically consist of drops of blood or other bodily fluids, and the results indicate the presence or absence of specific pathogens.

At Mora, we are directly involved in the manufacturing of these microfluidic chips. Our clients are primarily the manufacturers of diagnostic devices, with whom we collaborate to produce microfluidic chips tailored to meet strict technical and medical requirements.

These chips are integrated into diagnostic systems that use a wide range of technologies, depending on the specific application — including infrared detection, ultrasound, or genetic analysis. Their strength lies in their ability to detect elements at the molecular level using very small sample volumes: a single drop of blood, sweat, or another bodily fluid is often enough.

The applications are numerous: disease detection, genetic screening, biomarker research, as well as quality control in the food industry—such as detecting traces of gluten. This wide range of uses makes microfluidic chips a key enabler in the advancement of bioproduction and personalized diagnostics.

The fundamental principle of microfluidics is based on manipulating extremely small amounts of liquid through networks of microchannels. When a sample—such as a drop of blood—enters a microfluidic chip, it is divided into a multitude of micro-droplets, sometimes numbering in the tens of thousands. Each droplet can then be analyzed individually. This process enables highly precise analyses, often supported by statistical models, to confirm or rule out the presence of a biomarker, disease, or specific agent.

There is a wide variety of microfluidic chips, with different architectures depending on their intended use. However, the principle of sample fragmentation and multipoint analysis remains central to many applications.

What types of microfluidic chips does MORA Group manufacture?

The microfluidic chips we work on incorporate complex networks of microchannels, which are essential for guiding the liquid sample, fragmenting it into micro-droplets, or directing it toward a targeted analysis zone.

These components require an extremely high level of precision. Some applications demand the fabrication of channels as small as 20 to 40 microns, with dimensional tolerances within just a few microns. This degree of accuracy is what enables diagnostic machines to deliver reliable results.

We have notably developed microfluidic chips for the IPGG (Pierre-Gilles de Gennes Institute), a leading research organization in France specializing in microfluidics. The institute collaborates with a wide range of partners across various application fields. Our work has included not only the manufacturing of high-precision microfluidic chips but also the laser welding assembly of components.

Qu’est ce que l’IPGG 

IPGG is a French interdisciplinary research center specialized in microfluidics and nanofluidics. It is affiliated with PSL University and brings together teams from ESPCI, ENS, Institut Curie, and Chimie ParisTech. IPGG combines both fundamental and applied research, relying on a multidisciplinary team of physicists, biologists, chemists, and engineers to develop new microfluidic technologies

Indeed, in all applications, microfluidic chips must be hermetically sealed without obstructing the channels or compromising their functionality.

Pourquoi souder une puce microfluidique ?

To begin with, laser welding technology is not new; it was already in use more than twenty years ago, particularly in the automotive industry for assembling sensors. Even then, it proved to be an effective alternative to other assembly methods, including in complex and automated architectures.

When it comes to microfluidic chips, however, the level of precision required changes drastically. Accuracy becomes critical. The components are smaller, the tolerances much tighter, and every weld must be perfectly controlled to ensure the sealing of microchannels and the reliability of diagnostic performance.
The challenge, in this context, isn’t the welding technology itself—but rather adapting it to micro-scale assemblies, where the slightest deviation can compromise the system’s functionality.

The manufacturing of a microfluidic chip typically begins with the injection molding of a base component, which serves as the main support. This is where the microchannels are formed with the high level of precision needed for the system to function correctly.

But the molded part alone is not enough! To become operational, it must be sealed. A flat film is added on top as a cover to close off the microchannels. The goal is to achieve a perfectly airtight assembly that allows for controlled fluid circulation. This step requires a welding or bonding process that can join the two components without deforming the delicate structures of the molded part.

Why use laser welding for this type of product?

Until a few years ago, microfluidic chips were mainly assembled using chemical processes, particularly adhesive bonding. These techniques had several drawbacks: long processing times, complexity in industrial-scale production, and—most importantly—the use of potentially harmful chemicals. This poses a significant issue in medical environments, where material purity is critical.

In this context, Mora made the strategic decision to offer laser welding as an assembly solution. This technology offers several advantages: it is fast, clean, and easily scalable for industrial production, and it does not introduce any foreign materials. Only the properties of the original plastic components are utilized. This last point is particularly important for diagnostic and biomedical applications, where any external contamination must be avoided. Laser welding has therefore established itself as a reliable, clean solution that meets the strict requirements of the sector.

At Mora, we validated this approach through a Proof of Concept (POC), which allowed us to demonstrate that laser welding can achieve all three critical objectives: perfect sealing in highly targeted areas, reliable mechanical strength, and—most importantly—strict compliance with the micro-precision required by the chip’s structure.

It’s a true technical challenge, as the welding must be done without obstructing the surrounding microchannels. Some areas of the part feature channels as small as 20 microns in height, with tolerances of just a few microns in both width and depth. The welding process must therefore be extremely localized, precisely controlled, and highly repeatable.

Another major advantage of this process is the ability to integrate inline camera-based inspection, enabling automatic quality control of welds in critical areas.

Today, we are already using highly specialized laser welding machines. However, as volumes increase, our goal is to integrate them into fully automated production lines to ensure scalability, repeatability, and productivity.

What are the different types of laser welding used for this kind of application?

In the field of laser welding for assembly, three main technologies stand out, each suited to specific needs depending on the geometry of the parts and the sensitivity of the areas that must be preserved:

  • Contour laser welding: In this approach, the laser beam follows a precise path around the weld area. The laser moves along the microchannels, following a defined trajectory. This method is well-suited for complex shapes and highly localized welds.
  • Mask-based laser welding: This technique involves projecting a laser beam across the entire surface, while protecting sensitive zones with a copper mask. The mask shields areas such as fluidic channels from exposure to heat. The laser sweeps the surface, heating only the unmasked regions. This method is particularly suitable for assemblies that require strict preservation of functional areas..
  • Hybrid technology: There are also combined processes that leverage the advantages of both contour and mask-based welding, offering greater flexibility and precision depending on the application.

To optimize the laser welding process, Mora chose to use mask-based assembly.

Could you tell us a bit more about mask-based laser welding?

To ensure a reliable and repeatable assembly, Mora has implemented a tightly controlled laser welding process. It all begins with precision fixturing: the molded component is first positioned on a dedicated support, then the sealing film is placed on top. This step is critical, as it requires strict flatness tolerances.

To meet these demanding requirements, Mora developed a dedicated film-guiding system to ensure perfect flatness of the entire assembly prior to welding. A glass plate is then applied to apply uniform pressure across the stack. The copper mask, which defines the weld zones, is integrated into this glass plate.
The laser scan is carried out with extreme precision: only the areas exposed by the mask are welded. To achieve this, the mask itself must be machined with even greater precision than the final part, as beam diffraction can occur through the thickness of the mask—requiring exceptionally high-quality machining.

This level of precision led Mora to collaborate with specialized partners for both mask fabrication and laser welding. Thanks to this rigorous approach, the results achieved fully met expectations in terms of accuracy, with tolerances kept within just a few microns.

Today, the laser welding assembly process developed by Mora is capable of meeting a wide range of industrial needs—particularly in the demanding fields of medical diagnostics and microfluidics. Few players have mastered these technologies with such precision, giving Mora a unique position in this high-precision market.

Are there many of you who have mastered this technology?

Not really! That’s precisely why Mora is actively involved in a consortium of French stakeholders united around a common goal: to revive and structure a true microfluidics industrial sector in France. While our country has long been at the forefront of research in this field, that leadership hasn’t always translated into local industrialization.

The technology exists, the expertise is there—but what needs to be strengthened now is the production ecosystem. The COVID-19 pandemic and the rise of genetic testing have acted as catalysts for awareness, highlighting the strategic importance of these technologies for both public health and industrial sovereignty.

At Mora, this ambition is reflected in close partnerships with research organizations such as the Pierre-Gilles de Gennes Institute, in collaboration with prestigious institutions like the Institut Curie. This dialogue between fundamental research and industrial know-how is key to developing concrete, locally manufactured solutions that meet today’s medical and technological challenges.

How do you see the future of this technology that Mora has mastered so well?

Over the past two years, the field of microfluidics has experienced real momentum. Whether in research institutions or, more recently, in the industrial sector, initiatives are multiplying—driven by healthcare, innovation, and sovereignty challenges. The ambition is clear: to position France as a major player in this technology, building on its internationally recognized excellence in medical research.

MORA Group is fully committed to this dynamic—both in laser welding for assembly and in plastic injection molding. The upcoming projects already present new, even more demanding technical constraints that will require us to explore advanced injection technologies.

Each new development is a true challenge, especially in terms of precision, but it’s also what fuels our passion and commitment. Microfluidics is a field where every detail matters—and it is precisely in this level of rigor that MORA Group finds its purpose and legitimacy.

Metrology: precision driving quality and performance at Mora Group

Metrology plays a key role in the quality assurance of industrial parts, from moulds to complex thermoformed parts. A veritable science of measurement, it guarantees compliance with the most stringent requirements. It is therefore an essential link in securing every stage from development to series production. Vincent Collard tells us more about metrology in MORA Group’s processes.

Bonjour Vincent, Pourriez-vous nous décrire votre parcours professionnel ?

I’m Vincent Collard, Technical Director of the MORA Group and a mechanical engineer with a degree from UTC Compiègne.
After starting my career in subcontracting, I spent 15 years in the automotive industry, where I developed engine sensors and mechatronic systems for major manufacturers such as PSA, Renault, BMW and Ford.
There I managed teams and supervised the entire project lifecycle, from design to production.
I then took on new challenges as a key account project manager in the solar power plant sector, managing major projects for EDF and Aéroports de Paris.

Today, thanks to this experience in managing complex projects, I’m able to support MORA’s clients with rigour and expertise.

Can you explain what metrology is?

Metrology is the art of accurately measuring the parts we manufacture, in order to validate their conformity with the customer’s drawing. It is based mainly on the dimensional criteria defined in the drawing: lengths, diameters, thicknesses, locations, etc. and above all the associated tolerances.

We have several stages in our metrology process.
The first stage is exhaustive metrology. This involves measuring all the dimensions in the drawing on the first parts to come out of the mould. This stage is often carried out by specialist external laboratories.
After this phase, we make any necessary adjustments. At the end of the development process, we again carry out a full metrology test to definitively validate that the part conforms to the design.

However, what is very important to understand is that not all dimensions have the same level of importance. Some dimensions are considered critical or significant. These are marked on the plan with specific identifiers. These critical dimensions are generally taken from the customer’s product FMEA. These are dimensions which, if not respected, could lead to malfunctions, safety problems or regulatory non-compliance.

These critical ratings therefore receive special attention. Generally speaking, they are dealt with in two ways, often combined. Firstly, we carry out capability studies during development to assess whether the dimension is well under control in relation to the tolerances imposed. We then monitor production to ensure that the dimension remains compliant throughout the manufacturing process.

In practical terms, during development and whenever the product changes, such as after a mould rework, we carry out capability studies to check that the dimension is correctly centred and that it is capable, i.e. compliant and stable. This work continues right through to the final phase, when the initial sample report (PPAP in the automotive sector, or QO in the medical sector) is submitted.

In series production, the monitoring of critical dimensions is very often required. It may be carried out at the start and end of each batch or sometimes every 8 hours, depending on the customer’s requirements.

What specific process or organisation have you put in place at MORA GROUP for this expertise?

At Mora, we have set up a specific organisation to manage all this seamlessly. We identify critical dimensions at an early stage in the development process and monitor the continuity of measurements between development and production, to avoid any measurement discrepancies or biases.

We pay particular attention not only to the measurement of parts, but also to the quality of the measuring equipment itself. The equipment must be suitable and accurate, and the results must be repeatable and reproducible – in other words, reliable, whatever the operator.

To achieve this, we systematically carry out R&R (Repeatability and Reproducibility) studies on the measuring equipment used for these critical dimensions. In some cases, our customers also carry out their own checks upon receipt.

There are two possible situations:

Correlation of measurements: we compare our results with theirs, looking for any bias. Ideally, this would involve using the same equipment and the same fixtures. We sometimes suggest developing duplicate set-ups to limit differences, but this isn’t always feasible because our customers don’t always have the same machines as we do.

Full delegation of measurement: some customers prefer to delegate measurement to us and validate our metrology reports, capability studies and certificates. In this case, Mora is responsible for batch release.

Another important point is that some parts are particularly complex to measure, for example when they are massive or have significant material shrinkage. This makes metrology even more complicated, as achieving tolerances of ±0.02 mm on such parts requires very high levels of precision. At Mora, we have experience of this type of part, and our procedures guarantee rigorous monitoring and reliable measurements.

How does expertise in metrology represent an asset for Mora?

It’s not just the fact of doing metrology that’s an asset. It’s the internal organisation dedicated to dealing with it that makes all the difference at Mora Group.
When I took over as Technical Director in 2016, quality was not under my authority. This could have led to some cumbersome exchanges.
At the time, the Quality department provided the measurement reports, without being involved in the decision whether or not to rework the moulds. This meant longer lead times and a lack of efficiency in the event of a challenge from the Technical Department and the need for further analysis.

In 2019, I integrated development quality directly into my team. Since then, measurements, analyses and decisions have been taken smoothly and quickly.

Quality, project managers and tooling experts work together on a daily basis. As soon as there’s a question about a measurement, we talk directly to each other, arbitrate on the same day and make rapid adjustments. This enables us to speed up fine-tuning, prioritise actions more effectively and avoid silos between departments.

This integrated approach is a real differentiator compared with other companies. I see it every time I present our organisation to customers. They immediately see the benefit and often remark on it. In their own structures, they often still have a strict separation between quality and technical, which slows them down.

We have also integrated tool purchasing into the department. This allows us to control internally all decisions relating to additional costs or technical choices for moulds, while always remaining consistent with the project challenges.

Sterilization: a key expertise ensuring safety and quality at Mora Group

Sterilization is a key stage in the manufacture of devices for the medical and pharmaceutical sectors. To understand the challenges involved, Vincent Collard shares his experience of this demanding process, which has become a real confidence-building factor for our customers.

Hello Vincent, could you describe your career path for us?

I’m Vincent Collard, Technical Director of the MORA Group and a mechanical engineer with a degree from UTC Compiègne. I began my career in subcontracting before spending 15 years in the automotive industry, where I developed sensors for engines and mechatronic systems for customers such as PSA, Renault, BMW and Ford. I managed development teams and supervised the entire project lifecycle, from design to production. I then decided to take on new challenges by becoming a key account project manager in the solar power plant sector, working with EDF and Aéroports de Paris on large-scale projects. Today, I put this experience in managing complex projects to work for MORA, supporting our customers with rigor and expertise.

Today, I put this experience in managing complex projects to work for MORA, supporting our customers with rigor and expertise.

Can you explain sterilization at Mora Group?

Mora Group has been involved in product sterilization for almost ten years. This process mainly concerns products manufactured in cleanrooms and intended for the medical sector. We had noticed that some of our long-standing customers were sterilizing their parts themselves as soon as they received them.

As a rule, sterilization takes place at the final stage of the process. Once the products have been injected and packaged, they undergo sterilization before being sent to the end customer.

Mora Group’s commitment to sterilization management processes was prompted by the needs of a long-standing customer developing a pre-filled, single-use auto-injector.

This is a needle-free medical injection device, with MORA injecting the plastic components. As the drug comes into direct contact with the thermoplastic parts before being administered to the body, this is a particularly critical product. It is therefore essential to sterilize the injection nozzle assembled with its cover, a part manufactured by MORA, in order to eliminate any risk of infection for the patient in the event of contamination of the drug.

To guarantee optimum mastery of this requirement, we have called in specialists to deepen our knowledge and develop our skills, as well as our sterilization processes. However, this sterilization stage is not carried out in-house: we rely on subcontractors who are experts in this field.

In concrete terms, we deliver the packaged products to a service provider who takes care of sterilization. Once sterilization has been completed, the products are shipped directly to the end customer.

Can you explain what sterilization actually means?

The sterilizer can use a variety of methods, including radiation sterilization (X or Gamma), heat sterilization (dry or wet), and ethylene oxide (EtO) gas sterilization.

To date, we have outsourced gamma radiation sterilization, a technique widely used in the medical and pharmaceutical sectors. Its main aim is to eliminate any form of contamination present on the product (micro-organisms). These include bioburden and endotoxins, which are contaminants requiring strict elimination.

Gamma rays are used to neutralize these elements at doses of between 25 and 50 kGy, guaranteeing a level of sterility in line with regulatory requirements and industry standards.

Can you tell us more about your sterilization methodology and processes?

There are 4 main stages in the sterilization process.

The first step is to validate the sterilization method, a key phase in the development and pre-project phases. This validation confirms the effectiveness of the chosen technique. In our case, we use the VD max 25 method, which requires rigorous evaluation. It is based on determining the population of micro-organisms present, in compliance with sterilization standards.

To do this, we check the level of bioburden on products according to our manufacturing process. This analysis enables us to determine the sterility dose required to guarantee the eradication of contaminants. This minimum dose must be less than 25 kGy, which represents the minimum sterilization threshold. On the qualified batch, the products are subjected to treatment at the verification dose, followed by rigorous monitoring to ensure that they are perfectly sterile.

There is a direct link between the level of product bioburden and the sterility dose applied. Once the products have been processed, their sterility is checked to verify the effectiveness of the process. This step is the final validation of the sterilization method used.

The sterilization process must also be defined according to the product packaging, whether small containers, cartons or full pallets. In the case of full pallets, these are passed through sterilization tunnels, where they are exposed to gamma radiation treatment, ensuring sterilization of all the products they contain. This stage takes place directly at the sterilizer.

For qualification, we generally have three pallets processed at the same time. These are fitted with radiation dosimeters, positioned on all the cartons. The aim is to ensure that even the carton in the middle of the pallet receives the minimum dose of 25 kGy required for effective sterilization. This step ensures that all products receive a level of irradiation within the set tolerances of 25 to 50 kGy.

This process is known as mapping, and is an essential validation phase in the development process. At the end of this stage, we can guarantee that all products, in their original layout, have received the radiation dose required for sterilization.

It’s important to note that mapping is directly linked to part density and volume, as gamma rays must pass through cartons and products. Once the mapping has been validated, it is specific to the initial sterilization conditions.

Any modification to the product – be it a change of design, material, quantity or even packaging – requires a new cartography. Mapping validation is carried out at a given point in time, and remains valid only as long as the product and packaging parameters remain unchanged.

Sterilization is a particularly critical stage, as it can have a direct impact on patient safety. A flaw in this process could have serious consequences, which calls for absolute rigor and a well-defined methodical framework.

This is why a strict, routine protocol is implemented during series production, with checks carried out every three months. During the pre-production phase, these checks are even more frequent, being carried out for each production batch. This process is logistically demanding and requires precise monitoring: for each production run, representative samples are taken under the same manufacturing conditions, then sent to the laboratory for specific tests.

These tests include LAL (bacterial endotoxin tests) and Bioburden, which are used to check the product’s bioburden and endotoxin levels, and ensure that they remain within thresholds compatible with the defined sterilization ranges. This control protocol is systematically applied to sterilized products.

At Mora, we have also developed in-house product particle control, an essential step in the manufacturing process. This is an in-process control, carried out at each batch to measure the number and size of particles present on the parts produced.

To achieve this, we use a liquid phase particle counting method. The product is immersed in water after being “cleaned”, as it were, of any contaminants. The wash water is then aspirated with a probe, and analyzed by passing in front of an optical cell. This technology, enabled by a special machine, precisely identifies the quantity of particles present in different size ranges from 10 µm to 50 µm and more.

The number of particles detected is then related to a unit of surface area, a measurement expressed in CFU (Colony Forming Units). This analysis enables us to check whether the product complies with the defined cleanliness requirements. In this sense, it helps to qualify the product as clean and suitable for sterilization.

All these steps guarantee a rigorous sterilization process that complies with current standards, ensuring the safety and quality of products delivered to customers.

How are logistics managed at Mora?

As mentioned above, once our parts have been produced, they are sent to the sterilizer. After processing, they are shipped directly to the end customer. However, we manage all the logistics and documentation associated with sterilization.

We are responsible for collecting and transmitting certificates of conformity. These documents include laboratory certificates attesting to the sterilization dose applied, LAL and Bioburden test reports, and the irradiation certificate validating that the pallets have received the minimum required dose in kilograys.

All these documents are then sent to the customer. However, due to the delays involved in issuing the certificates, customers may receive their pallets before these documents have been received. Only after all the sterility and sterilization certificates have been analyzed and validated can the customer officially release the batches for use.

It’s important to distinguish between sterilization and sterility.

  • Sterilization is carried out by the sterilizer, who irradiates the products with a dose of between 25 and 50 kGy (in this case). His role is limited to the application of the treatment.
  • Sterility, on the other hand, is guaranteed by a series of controls and certificates confirming that the irradiation applied has indeed achieved the required level of sterility.

How do Mora Group customers perceive this know-how?

Many customers and prospects are particularly interested in outsourcing this management, which represents a real differentiating advantage for Mora compared with other plastic injectors. The ability to offer this comprehensive service is an essential added value, particularly for players in the medical and pharmaceutical sectors, who are looking for partners capable of managing these complex requirements.

In addition to integrating sterilization right from the project phase, in particular by validating the method and determining the sterilizing dose, Mora also handles all the logistics involved in this process.

This process goes far beyond conventional plastic injection molding production. It implies rigorous monitoring, an investment in logistical time and quality assurance. This expertise enables Mora to position itself as a trusted partner, capable of meeting the sector’s most stringent requirements.

We have chosen to bring this skill in-house, as it is fully in line with our global approach to managing the cleanliness and pollution of our products. This expertise is essential to guarantee rigorous control and perfect mastery of our internal processes.

To reinforce this approach, we have recruited a quality specialist in this field. Her role is central: she ensures internal controls, supervises interactions with the laboratories carrying out the tests, and ensures that our procedures comply with current standards and requirements. This internal integration enables us to optimize our monitoring, reinforce our responsiveness and ensure exemplary traceability throughout the process.

More and more major customers are looking to delegate the management of sterilization and its follow-up, which reinforces the value of our offer. However, it is essential to remember one crucial point: despite our key role in operational and logistical management, final responsibility for batch release and validation as sterile still lies with the customer.

Our mission is to ensure that the process runs smoothly – from manufacturing, through coordination with laboratories and sterilizers, to product release. We carry out these steps in practice, but the formal, binding act of batch release remains the responsibility of the end customer.

As part of our commitment to corporate social responsibility (CSR) and in order to support our actions in favour of the ecological and energy transition, Mora Group is proud to announce that it has joined the Coq Vert community, an initiative supported by Bpifrance and ADEME.

This membership marks a further step in our Group’s environmental strategy, demonstrating our determination to make an active contribution to building a sustainable economic model that reconciles industrial performance with the preservation of natural resources.

Why join the Coq Vert community?

The Coq Vert community is much more than just a network: it brings together almost 2,500 business leaders committed to a voluntary approach to meeting major environmental challenges. By joining this group, Mora Group intends to play a full part in this collective dynamic and is committed to :

  • Reduce climate disruption by adopting practices in line with carbon neutrality targets and investing in initiatives to help adapt to climate change.
  • Make the ecological transition a necessity, a source of value creation and sustainable employment.
  • Encourage, disseminate and promote technological and organisational innovation to accelerate the ecological transition of our industrial processes and products.
  • Mobilise and unite our professional ecosystem by raising awareness of environmental issues among our partners, employees and customers.
  • Make the ecological transition an opportunity to create sustainable value and responsible economic development.

Support to accelerate our transformation

Joining the Coq Vert community opens the way to a structured framework and concrete resources, enabling us to advance our environmental commitment:

  • Specialised training: we now have access to exclusive training modules and educational resources that enhance our expertise in the fields of energy and ecological transition.
  • An active network: through regular meetings, workshops and events, we benefit from a forum for dialogue and sharing with other committed players, encouraging the exchange of best practice and the emergence of collaborative initiatives.
  • Increased visibility: by highlighting our actions, our participation in this community enables us to promote our environmental projects to our stakeholders and inspire other companies to follow suit.

Mora Group: committed to a sustainable future

For several years now, Mora Group has been fully integrating environmental and social issues into its business. This is illustrated by our participation in the Ecovadis programme, which assesses and values companies’ CSR performance. Joining the Coq Vert community represents a natural extension of this approach, and an additional lever for stepping up our efforts to promote the ecological transition.

We are convinced that this transition should not be seen as a constraint, but as an opportunity for transformation and innovation. It is forcing us to rethink our production models, to invest in sustainable technological solutions and to strengthen our role as a responsible player in our sector.

Beyond our own actions, our ambition is to unite all the stakeholders with whom we work: customers, partners, employees and suppliers. By collaborating with local and international players, we aim to contribute to a collective dynamic capable of meeting today’s climate and environmental challenges.

Mora Group has chosen to combine economic performance with environmental responsibility. By joining the Coq Vert community, we are reaffirming our role as a committed leader and our determination to play an active part in the ecological and energy transition, in partnership with players who share the same values.

To find out more: : https://www.bpifrance.fr/communaute-du-coq-vert

Download the Coq Vert manifesto: Le manifeste

Development: a strategic pillar of innovation and performance at Mora Group

I’m Vincent Collard, Technical Director of the MORA Group, and a mechanical engineer with a degree from the UTC in Compiègne. I started my career as a project manager in the subcontracting sector, then spent 15 years in the automotive industry as a Tier 1 supplier.

I worked on the development of sensors for engines, gearboxes and mechatronic systems for customers such as PSA, Renault, BMW, Ford, Fiat, Mazda, Maserati and many other brands in France and internationally. I managed development teams of up to 30 people and oversaw the entire project lifecycle, from design to production.

This experience enabled me to strengthen my management skills and the management of complex projects. I then moved into a different sector, becoming a key account project manager for solar power plants, where I managed projects for customers such as EDF and Aéroports de Paris.

I then joined MORA as a project manager, before becoming Technical Director.

What distinguishes our approach at Mora is that all development is located in France, at Chambost-Allières. Our team works on projects and parts to be manufactured at our sites in France, Portugal and Romania, depending on the needs of the group. Manuplast, our Swiss subsidiary, is autonomous, but we also contribute our technical expertise on certain issues. We manage a wide range of projects for the medical, automotive and industrial sectors. All products manufactured within the Mora Group have necessarily passed through our development team.

As Head of Development, I manage a small team of around ten people:

It includes the two project managers and the person in charge of industrial methods. The latter specialises in special machines and peripherals at the press exit. She helps us to define the presses, draw up the specifications, validate the equipment, ensure that it is put into operation and carry out all the on-site qualifications.

  • Since 2019, quality has been integrated into development. This means that we can work more smoothly in project mode. We have an engineer in charge of quality-related documents, in particular qualifications, which are particularly demanding in the medical sector, with IQ, OQ, PQ reports, etc. We also develop protocols, i.e. preliminary documents, and define qualification criteria with customers. We also develop the protocols, i.e. the preliminary documents, and define the qualification criteria with the customers. The whole process is supervised by a validation master plan drawn up by the Quality Engineer.
  • The quality engineer also draws up the measurement programmes on 3D machines, the R&R studies qualifying these measurements and the capability calculations qualifying the products. We also carry out the in-house fitting required for these measurements.

Le service comprend également une contrôleuse Qualité, qui travaille sur les rapports de métrologie. Elle alimente les différents rapports Qualité par ses analyses et inspections sur pièces et ses mesures.

A mould expert with 30 years’ experience is both the tool expert and the tool buyer. He ensures consistency in exchanges with mould makers, using a common language. Under his supervision, two press set-up technicians are responsible for injection testing. They adjust the injection programme, carry out all the necessary tests and suggest improvements to optimise the processes.

The cost estimator is responsible for assessing the costs of all the RFQs we receive. These estimates are then sent to the sales department. There is a real continuity within the Technical Department between the costing being carried out and the project being taken over by the project manager. I think this involvement is essential, because the department takes ownership of the project, being responsible for both the costing and the project management.

We’re a relatively small team, but we work very closely together, which means we can be extremely responsive. The integration of development quality, mould purchasing and setting technicians within the department enables us to operate in a very coherent way. Working in a vacuum encourages fluid, rapid communication, which considerably improves responsiveness and the quality of information exchanged. This organisation is a real strength, giving us agility and fluidity in the management of our projects.

Development at MORA is special because we don’t design our own plastic parts. We respond to customer requirements, often defined by a specification, a 3D model or a customer drawing, as the project progresses. Our responsibility is not to design the part, but to work closely with the customer to manufacture it, hence the term ‘co-development’. We have to ensure that the part is correctly processed, that it injects optimally and that it is manufactured in accordance with the requirements. To achieve this, we take into account input data relating to quality, production capacity and the manufacturing environment.

From the 3D part supplied, the first step is to produce a DFM (Design For Manufacturing), where we recommend adjustments to make the design more realistic for our process. For example, for the mould, we indicate modifications such as undercuts, ejectors, injection points and parting lines. In short, our job is to design the means to manufacture the part in accordance with the customer’s requirements.

The customer can provide details of the production environment, for example in the medical sector, where clean environments are required, such as ISO 7 or ISO 8 rooms.

From the outset, we have to plan for the manufacture of the injection mould and its installation on the production line. We are increasingly evolving from an injector to a manufacturer, integrating automated machines to manage downstream processes. Our role is to ensure that the part is produced according to the customer’s expectations, in terms of quality and capacity.

From there, we design the mould, taking into account the optimisation of part injection, mould ejection and positioning. It’s also essential to think about peripherals, such as how the part can be picked up by a robot for packaging or decoration. We need to anticipate very early on the processes required to meet the customer’s expectations. We often have a great deal of freedom in the design of the tools, with the customer mainly defining the requirements in terms of functionality. This leaves our team with the responsibility of designing the industrial resources to meet their requirements.

We work in project mode, which means that the project manager plays a functional hierarchical role. He or she is the customer’s single point of contact, enabling him or her to maintain an overview of all the project’s input and output data. Procedures must not be seen as a constraint; they must be transformed into effective tools for monitoring and ensuring the smooth running of the project.

Development is managed according to an internal procedure, no. 20, which includes six milestones called PR (Project Review), from PR1 to PR6. Each milestone marks a project review point, with specific input and output data. I take part in all these project reviews, which have to be signed off before moving on to the next milestone. As long as there are open actions, we can’t move on to the next review. This process allows us to structure and phase development over time.

The process begins after the contract review, which marks the official launch of the project by the sales department (Kick off). Once the order has been received, the project can begin. I appoint the project manager and the associated team, which constitutes the handover between the quotation/offer phase and the project phase. The project manager The project manager then receives the budget, which includes the amount of purchases and the number of hours allocated to the project. After the contract review, the development procedure is launched.

RP1 consists of a 63-points questionnaire that we have to answer based on the project’s input data. It checks that the specifications are complete, that all the information is entered in the ERP system, and it defines the team, the schedule and the budget. If everything is in order, this means that the team has all the data it needs to start the project. This stage freezes the definition of the industrial means of implementing the product, in line with the customer’s requirements. If everything is in order, I sign the RP1 to validate this stage.

Between RP1 and RP2, we order all the necessary manufacturing resources, such as moulds, peripherals and special machines. At the same time, we validate the design of the equipment using a verification checklist. Another validation document covers the acceptance of the equipment, with a new checklist to be completed. These steps ensure that the design is validated and that the manufacturing equipment is ready for the next phase of the project.

It is dedicated to the first tests, with a new checklist to be validated following the tests carried out on the machines. Several fine-tuning and metrology loops are carried out to ensure that all the conditions are met and enable this stage to be validated. These tests confirm that the manufacturing resources comply with the specifications before moving on to the next stage.

RP3 is linked to IS (Initial Samples) for the automotive and industrial sectors, or OQ (Operational Qualifications) for the medical sector. These are parts that we deliver to the customer, which serve as the basis for all qualifications. These parts must be representative of what will be produced in series. They are crucial because they validate the project with the customer and accurately reflect the production process.

If production takes place abroad, the project manager and tooling manager will travel to the site to guarantee conformity. In the medical sector, two qualifications are carried out: the QO, which is product-oriented, and the QP, which is process-oriented and entirely faithful to series production. These qualifications are essential to obtain customer acceptance before going into production

This confirms that we have received the customer’s validation feedback and that all the conditions have been accepted. It confirms that the part meets the customer’s requirements and that we can proceed to series production.

It marks the handover from development to production. It includes a detailed checklist with internal documents to be completed. This stage is used to check that production has all the necessary information, such as the control range, the product drawing and the means to manufacture the part… This is also the stage at which the production plant confirms that it agrees to take over development. It also serves as a check-up to assess the progress of the QP (Qualification Process) and to ensure that everything is in order before launching production.

RP6 takes place after approximately 6 months of production. It provides feedback on how the production process has gone, identifying what went well and what went badly. It also enables us to identify improvements to be made to the process. This stage is crucial for obtaining feedback from the manufacturing sites, in order to optimise methods and guarantee consistent quality across all the Group’s plants. A full financial review of the project is carried out, and any deviations from the initial costing are analysed. A comparison of the initial and actual schedules is carried out, with explanations given if there are any discrepancies. The aim is to take into account areas for improvement for future projects. RP6 is signed by myself.

The quality part of the development process is crucial, in particular to ensure that the final product meets the customer’s requirements. This includes documentation and the implementation of checking fixtures from the earliest stages of development. We are responsible for designing the checking fixtures used in production, such as specific fixtures with three-dimensional checks performed by 3D measuring machines (probing or optical).

The measurement programme is designed by our team. In very demanding sectors such as the medical sector, and when we have moulds with 64 cavities, we develop specific fixtures enabling us to simultaneously check all the parts produced from a mould.

These tools must be qualified to guarantee their accuracy and reliability when measuring parts. Once qualified, they are used to assess part conformity and determine the capability of each critical rib. These checking fixtures are then transferred to the quality teams at the production sites, who use them to ensure rigorous and constant monitoring, guaranteeing part conformity throughout the manufacturing process.

Quality during the project also involves ensuring that all the qualification documents and associated test sheets are properly drawn up, from the protocols to the final reports.

And there can be no good process without appropriate Risk Analysis and Process FMEA; this approach is taken by the Development Quality department, involving the entire project team.

The design of the cleanrooms that enable us to comply with ISO13485 was carried out by Mora’s development team. The entire 3D construction of the environment came from our department, with manufacturing being subcontracted. A new cleanroom was installed in 2017, followed by the second in 2019, the third in 2021, and the fourth in 2023. These facilities impose significant requirements in terms of cleanliness, clothing and environmental control.

Today, Mora is more than just an injector. Although injection moulding remains our core business, we have broadened our expertise by developing related processes and technologies such as leak-proof unit packaging, 100% camera control, automatic packaging, decoration and marking to ensure traceability. We have also put in place processes to manage the sterilisation of parts and guarantee their sterility.

At Mora, we master injection moulding, process automation and the validation of our processes and products through a rigorous procedure.

Our technical excellence lies in offering our customers the optimum level of automation in response to their economic, capacity and quality requirements.

At Mora, expertise in thermoplastic injection moulding goes hand in hand with extensive know-how in the decoration of injected parts. To give you a detailed insight into this business, we have gathered the testimony of Vincent COLLARD, Technical Director of the Mora Group.

I’m Vincent COLLARD, Technical Director of the Mora Group. I am responsible for the development team based in Chambost-Allières, which works for all our sites in France, Portugal and Romania.

My career as a mechanical engineer, which began at the UTC in Compiègne, gave me a wealth of experience as a project manager for  car manufacturers and in the field of solar energy for large power plants. In 2016, after several years at Mora as project manager, I took over as the group’s technical director.

« At Mora, the injection of thermoplastic parts is at the heart of our business. Decoration, or finishing, enhances this expertise by adding visual elements to injected parts. We apply decoration mainly using pad printing.

This technique uses a specific ink pad, designed to take ink from a mask of defined shape, then apply it precisely to the injected part.

This method ensures that the decorations are durable and robust.

Although other technologies, such as inkjet printing, exist, they are not as suitable in terms of durability and resistance over time. Pad printing therefore remains our preferred method for offering our customers durable finishes.

We use pad printing for a wide range of customers and applications. This technology enables us to decorate injected parts with great precision, meeting the requirements of a wide range of industries.

We work with customers in a wide range of sectors, including the medical sector. Pad printing can, for example, reveal graduations on syringes and Covid diagnostic control logos (positive/negative) on medical devices. This technology ensures that these markings remain visible and legible over the long term.

The versatility of pad printing means that brand logos can often be printed on a multitude of products, including DIY tools, household electrical boxes, perfume bottles and caps, and air conditioning units for vehicle interiors. Each part benefits from a precise and durable decoration, reinforcing the visual identity and perceived quality of our customers’ products.

« We’ve been pad printing for over 20 years. Over the years, technologies and machines have evolved, and we have constantly updated our equipment to stay at the forefront of innovation. Our multi-head machines, capable of applying different colours, have been complemented by sophisticated automatic lines.

These improvements allow us to integrate decoration perfectly with our core business of plastic injection moulding, offering complete, high-quality solutions. ».

«We are currently working on a major project involving automatic pad printing for the CrossJet element. This project is a perfect example of our ability to integrate advanced automation into our decoration processes.

The decoration for this project involves pad printing around a window and printing an arrow and a number. These markings are used to guide the user ergonomically when handling the product, making it easier to apply the medication..

On this product, two elements require particular attention: the cap and the cover.

For the cap, we use semi-automatic pad printing, enabling us to produce around 200 pieces per hour. This method is suitable for lower production rates, but ensures consistent precision and quality.

For the cover, which requires the application of two colours on two sides, we set up a fully automated production line capable of producing 1,000 parts per hour. This sophisticated robot is equipped with 12 mandrels and a system for automatic unloading of parts by a robot. A second robot then positions each part on another mandrel of the pad printing machine, which applies the two colours on both sides. A 100% camera check verifies the integrity of the pad printing, guaranteeing optimum quality. Once the decoration is complete, the parts are unloaded onto a conveyor belt for packing and dispatch.

This project has enabled us to take a significant step forward in terms of automation. Thanks to these improvements, we are now able to respond to even higher volumes. For example, we can switch from a 2-cavity rotary mould to a 4+4 cavity mould to increase our production capacity. We are able to adapt our processes to customer requirements.

We strive to develop optimised processes adapted to our customers’ requirements, while maintaining high synthetic yield rates (SRR). The OEE is a crucial indicator that assesses our ability to produce finished products over the course of a production day. It takes into account factors such as cycle time, machine downtime and time spent on quality. Our objective is to achieve an OEE of 90%.

This indicator is particularly important in interconnected processes, such as those involving pad printing and plastic injection moulding. As pad printing is directly linked to the injection moulding machine, it is essential that these two processes work in harmony. A problem on the pad printing line must not disrupt production upstream of the injection moulding machine

To avoid such interruptions, we have set up buffer systems. If a problem occurs on the pad printing line, the injection moulding machine continues to produce parts, which are stored in a buffer. When the pad printing machine is operational again, it can retrieve the stored parts and resume the process without interruption.

Having processes that run smoothly is essential if we are not to slow down the business. Through automation and rigorous process management, we ensure continuous, efficient production that meets our customers’ requirements while optimising our production capacity.

Automated pad printing lines minimise product handling, which is crucial for guaranteeing the cleanliness and integrity of decorations, particularly in the medical sector.

In our process, the cap comes out of the injection moulding machine, is picked up by a robot and placed directly on the mandrel. The robot then decorates the cap using pad printing and places it on a conveyor belt. The part is not handled until the end of the process, when it is placed in a cardboard box, which reduces the risk of contamination by human hands.

Our automated system makes it possible to produce two-colour pad printing in a single pass, considerably reducing the risk of quality defects that could occur if two passes were necessary

To validate the quality of each piece, we use 100% camera control. This final step ensures that all decorations meet our quality standards before the pieces are packed and dispatched.

At Mora, we stand out from our competitors who focus solely on pad printing thanks to our complete mastery of the manufacture of injected parts. This integrated expertise enables us to offer significant advantages:

We have the ability to automate the decoration process immediately after injection, which translates into high output rates and reduced costs. By avoiding the additional costs associated with transporting and handling parts, we can offer competitively priced products while maintaining superior quality.

Less handling of parts means less risk of impact and contamination. By minimising these human interventions, we can guarantee better part integrity, which is crucial for demanding sectors such as the medical sector.

Camera inspection is now an essential part of our process. Each part is inspected and qualified as soon as it leaves the production line. This ensures accurate and consistent pad printing, guaranteeing compliance with specifications in terms of template, dimensions and absence of defects such as run-outs. This rigour enables us to aim for zero defects

By integrating pad printing into our injection moulding process, we guarantee not only the decoration but also the overall quality of the part.

C Each stage is designed to optimise cycle time and part quality, strengthening our competitive position in the market.

We are very pleased to announce that Mora Group has just acquired Manuplast SA, a Swiss company based in Ballaigues, canton of Vaud.


Manuplast SA is ISO 13485 certified and has a great portfolio of capabilities in high added value sectors such as medical devices, high end watchmaking and other technical industries.

These capabilities will perfectly complement the existing know-how of the Mora group.

For more details, please consult our communication release below

Article dans DeviceMed, magazine de référence en matière de fabrication de dispositif médical

Spécialisé dans la production de pièces plastiques de haute technologie, le groupe Mora s’appuie sur un parc machines complet et moderne, des salles propres ISO7/ISO8 et, au travers de sa filiale Sofami, sur des moyens de fabrication de moules qui viennent d’être enrichis de 2 centres d’usinage.

Fort de plus de 50 années d’expérience dans la plasturgie, le groupe Mora réalise un chiffre d’affaires annuel de 35 millions € au service des secteurs du médical, de l’automobile et de la défense. Dès 1998, il s’est doté d’une salle de production en atmosphère propre. Un pas supplémentaire a été franchi en 2019, avec l’installation de 2 salles blanches ISO 7 pour son site de production de Chambost-Allières à 50km au nord-ouest de Lyon, qui s’est alors spécialisé dans la production exclusive de composants et ensembles pour les secteurs médical, paramédical et pharmaceutique.

A ce jour, le groupe met à la disposition de ses clients pas moins de 4 salles propres ISO7/ISO8 sur 1600 m2 et 34 machines électriques de dernière génération, ainsi que de nombreux équipements et services annexes pour des prestations partielles ou complètes. Outre des moyens de contrôle qualité de haute technologie, l’acquisition d’un appareillage de comptage particulaire a permis de gérer les risques de contamination à un niveau revendiqué par Mora comme le plus faible du secteur.

Le groupe Mora propose également son expertise dans la fabrication de moules d’injection, au travers de sa filiale Sofami, dotée des moyens de fabrication les plus modernes de la profession, et qui emploie 30 personnes. Pour faire face à sa croissance, Sofami vient de réceptionner 2 centres d’usinage 3 et 5 axes ultra-modernes.

Le groupe Mora se positionne comme partenaire dans le développement, la validation, l’industrialisation et la production à un très haut degré d’intégration et de qualité, et garantit une confidentialité absolue dans le déroulement des projets.

A voir sur le stand B98 de Pharmapack.

Antoine Gervais, 45, joined the family-owned Mora International group at the beginning of 2022 after having spent over 20 years in industry and services. A graduate of Supaero and with a Masters of Science from Stanford University, Antoine Gervais started his career with Dassault-Aviation in 2001, firstly in the engineering and design department in Paris then with the certification department in Bordeaux.

In 2006 he completed his education with an MBA from INSEAD then worked in turn for Jet Aviation, a leader in technical services for business aviation, then for SR Technics, a company specialized in aeronautical maintenance and engineering. In 2016 and until he joined Mora, he was Managing Director for the Swissport group’s airport activities in Geneva and Nice. In parallel, Antoine Gervais has been a Mora International board member for 5 years.

Clément Lacroix, Chairman of the Board of Directors of Mora International and representative of the next generation of the family-owned group’s shareholders, says: “We are delighted to welcome Antoine Gervais as managing director of Mora International. The years he spent on the company’s board of directors have paved the way for a natural transition to this executive role, in which he will be able to continue developing the company”.

Antoine Gervais says: “I am delighted to be back in an engineering and technical development environment. The company has high growth potential, so I began by meeting Mora International’s customers in order to consolidate existing partnerships and forge new ones over the long term. This announcement is also an opportunity to thank Jean-Pierre Lacroix very warmly, who has run the Mora International group for more than 30 years, expanding it and passing it on in a family setting”.

With 320 staff, Mora International is a high-tech industrial group specialized in plastics among other things for the medical, automotive and defence sectors. From design and development to the fabrication of tools and equipment and injection of plastic parts, Mora International controls the entire value chain for the benefit of a demanding and diversified clientele. Founded in France over 50 years ago, the group also operates in Portugal and Romania, and works closely with top-tier customers.

Further information can be obtained from Carole Breton: 

carole.breton@mora-int.com

Phone : +33 (0)4 74 03 19 61

Let's prepare the future together

Do you have a project?
Do you need any information? Advice?